A bioengineered chewing gum has demonstrated the ability to reduce oral human papillomavirus (HPV) levels by up to 93% in samples taken from head and neck cancer patients, according to research published this week. The experimental gum contains lab-engineered proteins designed to bind and neutralize microbial targets in the mouth. In laboratory testing, a single dose of the gum's extract nearly eliminated two harmful bacterial species associated with oral disease, while leaving beneficial oral bacteria largely undisturbed. The findings suggest a potential low-cost, non-invasive approach to managing microbial risk factors linked to head and neck cancers, which are increasingly associated with HPV infection.
The research remains preliminary, with results based on oral samples and extract testing rather than full clinical trials in patients. Scientists caution that further studies are needed to confirm the gum's effectiveness in real-world use, determine optimal dosing, and assess long-term safety. If validated in larger human trials, the approach could offer a simple preventive tool for populations at elevated risk of HPV-related cancers, particularly in regions where vaccination and screening access remain limited. Independent experts not involved in the study described the concept as innovative but stressed that chewing gum would complement, not replace, existing HPV vaccination and cancer screening programs.
Independent reporting synthesized from primary wires and global correspondents.